

510(k) Summary

510(K) Owner's Name:	Tornier Inc.	
Address:	10801 Nesbitt Avenue South	
	Bloomington, Minnesota 55437	
Phone and Fax Numbers:	Phone: 952:426.7600	}
	Fax: 952.426.7601	.]
Name of Contact Person:	Janell A. Colley	
Date Prepared:	December 5, 2013	EC 0 5 2013
Trade or Proprietary Name:	Tomier Aequalis Humeral Nail System	- 2013
.Common or Usual Name:	Intramedullary Fixation Rod	
Classification Name:	Product Code: HSB	
·	21 CFR 888.3020	_
Legally Marketed Device to		
Which Your Firm Is	Tornier Aequalis Humeral Nail System, K082754	
Claiming Equivalence:		1
Description of The Device:	The Tornier Aequalis Humeral Nail System includes intramedullary nails	
	and screws. The Tornier Aequalis Humeral Nail is a straight, cannulated	
	intramedullary nail with a tapered distal diameter. Nails are provided in	
	right and left configurations with a 9mm diameter and 130mm length. The	
	proximal end of the nail contains screw holes in four axes for proximal	
	locking using 5mm cannulated or non-cannulated screws. The proximal	
	end of the nail also contains a cannulated polyethylene insert with screw	
	holes aligned with those of the nail. This insert is intended to help prevent	
•	the proximal screws from backing out. The distal end of the nail	•
	incorporates one screw hole for distal locking using 4.5mm screws. The	
	nail and screws are manufactured from anodized Ti-6Al-4V alloy.	
	The purpose of this 510(k) is to add 7mm or 8mm proximal diameter nails	
	in lengths of 130mm, 210mm, 230mm, 250mm, and 270mm lengths to the	,
illustration of the state of th	predicate system. The Tornier Aequalis Humeral Nail System is intended to provide	-
Intended Use of the Device:	temporary stabilization of various types of proximal and/or diaphyseal	
	fractures of the humerus. Types of fractures include, but are not limited to,	
	non-unions, malunions, malalignments, pathological fractures, and	
:	impending pathological fractures. Examples of specific indications	
	according to AO classification include Type A-Fractures, dislocated, Type	
	B Fractures, dislocated; Type C-Fractures, with intact humeral head, or	
	Humeral Fractures according to Neer-Classification (2, 3 and 4 part	•
	fractures).	
Technological'	The technological characteristics (material, design, sizing, indications,	1
Characteristics Compared	sterilization, and failure strength) of the Tornier Aequalis Humeral Nail	
To Predicate Device:	System are substantially equivalent to the predicate device.	
Summary of the	Non-clinical laboratory assessment/testing was performed to evaluate the	-
Nonclinical Tests	device performance per design requirements and risk analysis, including	
Submitted:	bending calculation comparisons and torque testing. All tests met the pre-	
The second of th	established acceptance criteria.	
Conclusions Drawn From	Based on risk analysis and acceptable results from testing, the Tornier	1
the Nonclinical and Clinical	Aequalis Humeral Nail System was found to be substantially equivalent to	
Tests:	the predicate device.	
IUSIS.	i die progrego de rice.	



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

December 5, 2013

Tornier, Incorporated
Ms. Janell A. Colley
Regulatory Affairs Manager
10801 Nesbitt Avenue South
Bloomington, Minnesota 55437

Re: K133376

Trade/Device Name: Tornier Aequalis Humeral Nail System

Regulation Number: 21 CFR 888.3020

Regulation Name: Intramedullary fixation rod

Regulatory Class: Class II Product Code: HSB

Dated: November 6, 2013 Received: November 7, 2013

Dear Ms. Colley:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office

of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number

(800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Mark N Melkerson -S

Mark N. Melkerson
Director
Division of Orthopedic Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure



Statement of Indications for Use

510(k) Number:

K133376

Device Name: Tornier Aequalis Humeral Nail System

DEC 0 5 20:3

Indications for Use

The Tornier Aequalis Humeral Nail System is intended to provide temporary stabilization of various types of proximal and/or diaphyseal fractures of the humerus. Types of fractures include, but are not limited to, non-unions, malunions, malalignments, pathological fractures, and impending pathological fractures. Examples of specific indications according to AO classification include Type A-Fractures, dislocated, Type B Fractures, dislocated, Type C-Fractures, with intact humeral head, or Humeral Fractures according to Neer-Classification (2, 3 and 4 part fractures).

Prescription Use X AND/OR
(Part 21 CFR 801 Subpart D)

Over-The-Counter Use___

(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NECESSARY)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Casevil-Hanley, Ph. 9

Division of Outhopedic Devices